5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug sales plunged. HIV drug sales looked good. And Gilead still has a boatload of cash.
The more interesting aspect of Gilead's third-quarter update, though, wasn't in its numbers, but rather in what the biotech's executives said in the quarterly conference call with analysts. Here are five things you need to know from that call. (Quotes courtesy of S&P Global Market Intelligence.)
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
€66.85
1.720%
The stock is one of the favorites of our community with 31 Buy predictions and 1 Sell predictions.
With a target price of 79 € there is a slightly positive potential of 18.18% for Gilead Sciences Inc compared to the current price of 66.85 €.
